News
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know
Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Novo Nordisk revealed on Monday that it will no longer work with Hims & Hers,
Despite Novo Nordisk (NVO) recently ending a partnership with Hims & Hers Health (NYSE:HIMS) to distribute its weight-loss ...
Meanwhile, Novo had agreed supply deals with Hims and several of its larger rivals. The idea was to give their existing ...
LOS ANGELES, June 23, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("H ...
A handful of prominent companies on Wall Street have seen some Seeking Alpha analyst activity, including both upgrades and downgrades. Among the group is Hims & Hers (NYSE:HIMS) and Shell (NYSE:SHEL), ...
MarketBeat on MSN1d
Why Hims & Hers Stock Could Be a Multi-Bagger in the MakingGross profit margins are typically a sign of strong (or weak) pricing power and market share, and a 73% margin tells investors all they need to know. Hims & Hers is an industry leader, and its ...
In this video, I will explain why Hims & Hers Health (NYSE: HIMS) crashed over 30% on Monday. Watch the short video to learn more, consider subscribing, and click the special offer link below. *Stock ...
StockStory.org on MSN2d
Hims & Hers Health (HIMS) Stock Trades Down, Here Is WhyWhat Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 29.2% in the morning session after Novo ...
Hims & Hers Health (NYSE:HIMS) recently announced the introduction of affordable access to Wegovy, a significant move aimed at improving obesity treatment options. This, along with strong Q1 2025 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback